Page 280 - Drug Class Review

Page 170 of 205
Drug Effectiveness Review Project

placebo 72.7 53 18.2 29.2 At week 30 significantly more patients in the placebo group were placed in a nursing home or had died than in the TAC 160 mg/d group (7% vs. 4%; OR 2.8; 95% CI: 1.0 – 7.8; P = 0.046); no significant differences between placebo and TAC 80 mg/d group (7% vs. 7%) Significant differences in favor of 160 mg/d TAC vs. placebo for CIBI (P = 0.002) and ADAS- A subgroup analysis revealed that patients with higher MMSE scores (18-26) did not benefit more No interaction between gender and TAC treatment on the ADAS-Cog score could be dete

Alzheimer classification: Mild-moderate

Primary Outcome Measures: CIBI; ADAS-Cog; FCCA Secondary Outcome Measures: ADAS-Noncog; ADAS-Total score; MMSE; GDS Timing of assessments: Baseline and every 6 weeks from treatment than patients with lower scores (10-17)
Groups similar at baseline: Yes
40- 80; 40-60-120; 40-80-120- Health Outcome Measures: Cog (P < 0.001)

tacrine 160 mg/d 73; 73; 72.8 48; 55; 51 17.1; 18.7; 18.8 30.9; 28.5; 28 Intermediate Outcome Measures: APOE-[epsilon]2-3 genotype

• • • • •

Final Report Update 1 Authors: Knapp et al. Year: 1994 POPULATION CHARACTERISTICS: Mean age (years): Sex (% female): Ethnicity: NR Other germane population qualities: MMSE • ADAS-Cog • OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs